Publications
5538 Results
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:3a(#10)
- Year
- 1998
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8809
A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:385a(#1483)
- Year
- 1998
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)
Chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (pts) with advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: Progress report.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:1a(#2)
- Year
- 1998
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8897
CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:373a(#1436)
- Year
- 1998
- Research Committee(s)
- Gynecologic
- Study Number(s)
- SWOG-9212
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma (SWOG 9212).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:361a(#1392)
- Year
- 1998
- Research Committee(s)
- Gynecologic
- Study Number(s)
- SWOG-9227 (GOG-114)
Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An intergroup trial (GOG, SWOG, ECOG).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:451a(#1737)
- Year
- 1998
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9242
Docetaxel (taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the Southwest Oncology Group (SWOG).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:453a(#1744)
- Year
- 1998
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9308
Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): An update of a Southwest Oncology Group study (SWOG 9308).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:314a(#1211)
- Year
- 1998
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9343
Androgen deprivation (AD) + 4-courses of fixed-schedule suramin in D2 prostate cancer (PCA) patients (pts): A Southwest Oncology Group phase II study.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:340a(#1310)
- Year
- 1998
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9343
Analysis of suramin (S) levels obtained from D2 hormone naive prostate cancer (HNPCA) patients (pts) treated with fixed bolus suramin: A Southwest Oncology Group study.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 17:97a(#374)
- Year
- 1998
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-9445